Phase I/II Study of Linperlisib Plus Chidamide for R/R Peripheral T-cell Lymphoma: a Prospective, Multi-center Study
Phase 1
Recruiting
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06083701
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing/China, China
🇨🇳Beijing Hospital, Beijing, China
The Choice of Treatment Methods and Efficacy of LABC
Not Applicable
Recruiting
- Conditions
- Locally Advanced Breast Cancer
- Interventions
- Procedure: Modified radical mastectomy for breast cancerProcedure: neoadjuvant therapyProcedure: Systematic treatment
- First Posted Date
- 2023-10-12
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06080620
- Locations
- 🇨🇳
Ying Xu, Beijing, China
Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy
Phase 1
Active, not recruiting
- Conditions
- Biliary Tract CancerPredictive Cancer ModelImmune Checkpoint Inhibitor
- Interventions
- Drug: Immune Checkpoint Inhibitors
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06074029
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, Beijing, China
First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma
Phase 2
Recruiting
- Conditions
- Gastrointestinal Neuroendocrine Carcinoma
- Interventions
- First Posted Date
- 2023-10-06
- Last Posted Date
- 2023-10-06
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06070740
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06063018
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
Not Applicable
Not yet recruiting
- Conditions
- Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma
- Interventions
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT06062563
- Locations
- 🇨🇳
YansongLin, Beijing, Beijing, China
Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
Recruiting
- Conditions
- Advanced Soft Tissue Sarcoma
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06062927
- Locations
- 🇨🇳
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
Health Economic Research on Oral Nutritional Supplements for Hospitalized Patients With Nutritional Risk
Not yet recruiting
- Conditions
- Nutritional RiskMalnutrition
- Interventions
- Drug: oral nutritional supplements
- First Posted Date
- 2023-10-02
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30000
- Registration Number
- NCT06062914
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Comparison of Al18F-NOTA-LM3 With 68Ga-DOTATATE and 68Ga-NODAGA-LM3 PET/CT in Patients With Well-differentiated Neuroendocrine Tumors
Phase 1
Recruiting
- Conditions
- Neuroendocrine Tumors
- Interventions
- Diagnostic Test: Al18F-NOTA-LM3Diagnostic Test: 68Ga-NODAGA-LM3Diagnostic Test: 68Ga-DOTATATE
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06056362
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
The Effects of Aronia Melanocarpa Extract on Obese Individuals With Impaired Fasting Blood Glucose
Not Applicable
Not yet recruiting
- Conditions
- Obesity
- Interventions
- Dietary Supplement: aronia melanocarpa extract
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 72
- Registration Number
- NCT06057389
© Copyright 2025. All Rights Reserved by MedPath